Skip to main content

Master of Public Health

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

AUTHORS

Avila D , Althoff KN , Mugglin C , Wools-Kaloustian K , Koller M , Dabis F , Nash D , Gsponer T , Sungkanuparph S , McGowan C , May M , Cooper D , Chimbetete C , Wolff M , Collier A , McManus H , Davies MA , Costagliola D , Crabtree-Ramirez B , Chaiwarith R , Cescon A , Cornell M , Diero L , Phanuphak P , Sawadogo A , Ehmer J , Eholie SP , Li PC , Fox MP , Gandhi NR , González E , Lee CK , Hoffmann CJ , Kambugu A , Keiser O , Ditangco R , Prozesky H , Lampe F , Kumarasamy N , Kitahata M , Lugina E , Lyamuya R , Vonthanak S , Fink V , d'Arminio Monforte A , Luz PM , Chen YM , Minga A , Casabona J , Mwango A , Choi JY , Newell ML , Bukusi EA , Ngonyani K , Merati TP , Otieno J , Bosco MB , Phiri S , Ng OT , Anastos K , Rockstroh J , Santos I , Oka S , Somi G , Stephan C , Teira R , Wabwire D , Wandeler G , Boulle A , Reiss P , Wood R , Chi BH , Williams C , Sterne JA , Egger M , , . Journal of acquired immune deficiency syndromes (1999). 2014 1 1; 65(1). e8-16

ABSTRACT

To describe the CD4 cell count at the start of combination antiretroviral therapy (cART) in low-income (LIC), lower middle-income (LMIC), upper middle-income (UMIC), and high-income (HIC) countries.

To describe the CD4 cell count at the start of combination antiretroviral therapy (cART) in low-income (LIC), lower middle-income (LMIC), upper middle-income (UMIC), and high-income (HIC) countries.

Tags: